APYX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
14.0M
+1.1%
13.9M
+11.2%
12.5M
-34.8%
19.2M
+48.8%
12.9M
Cost of Revenue
5.0M
+0.3%
5.0M
+9.8%
4.6M
-36.3%
7.2M
+56.4%
4.6M
Gross Profit
9.0M
+1.5%
8.9M
+11.9%
7.9M
-34.0%
12.0M
+44.6%
8.3M
Operating Expenses
9.6M
-10.4%
10.7M
+21.3%
8.8M
-26.6%
12.0M
+32.4%
9.1M
R&D
849.0K
+7.1%
793.0K
+3.7%
765.0K
-19.0%
944.0K
+17.9%
801.0K
SG&A
8.7M
-11.7%
9.9M
+22.5%
8.1M
-26.9%
11.0M
+32.6%
8.3M
Operating Income
-562000
+68.8%
-1804000
-106.2%
-875000
-8054.5%
11.0K
+101.5%
-756000
EBITDA
-375000
+76.7%
-1608000
-138.9%
-673000
-390.1%
232.0K
+139.2%
-592000
Net Income
-1806000
+41.2%
-3072000
-43.4%
-2143000
-72.8%
-1240000
+36.6%
-1955000
EPS (Basic)
$-0.04
+42.9%
$-0.07
-40.0%
$-0.05
-66.7%
$-0.03
+40.0%
$-0.05
EPS (Diluted)
$-0.04
+42.9%
$-0.07
-40.0%
$-0.05
-66.7%
$-0.03
+40.0%
$-0.05
Shares (Diluted)
44.0M
+0.4%
43.9M
+0.2%
43.7M
+3.7%
42.2M
+3.5%
40.7M
Apyx Medical (APYX) — Financials